文献速递妇科

Erastin通过膜铁转运蛋白介导的铁积累诱导子宫内膜异位症铁死亡

Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究探讨Erastin能否通过铁死亡退化子宫内膜异位病灶。在21例子宫内膜异位症患者的异位子宫内膜间质细胞中,Erastin处理增加总ROS、脂质ROS和细胞内铁,并诱导铁死亡;过表达膜铁转运蛋白(FPN)可消除此效应,敲低FPN则加速铁死亡。小鼠模型显示Erastin给药后异位病灶退化。

要点

  • Erastin可诱导异位子宫内膜间质细胞铁死亡并抑制病灶。
  • FPN下调导致铁积累,是Erastin诱导铁死亡的关键机制。
  • Erastin对正常子宫内膜间质细胞影响轻微,提示选择性。

核心结论

  • Erastin通过FPN介导的铁积累诱导异位子宫内膜间质细胞铁死亡,从而退化管理子宫内膜异位病灶。

研究设计与样本

  • 体内研究使用10只C57BL/6雌性小鼠建立子宫内膜异位症模型。

主要发现

  • 异位子宫内膜间质细胞(EESCs)比正常子宫内膜间质细胞(NESCs)对Erastin更敏感(P<0.05)。
  • Erastin处理EESCs后总ROS水平(P<0.05,vs对照)、脂质ROS水平(P<0.05,vs NESCs)和细胞内铁水平(P<0.05,vs NESCs)显著增加。
  • 铁螯合剂DFO及铁死亡抑制剂ferrostatin-1和liproxstatin-1可减弱Erastin对EESCs的细胞毒性(P<0.05,vs Erastin)。
  • EESCs经Erastin处理后电镜下观察到线粒体变短和浓缩。
  • Erastin诱导EESCs铁死亡伴随铁积累和FPN表达下降;过表达FPN消除Erastin诱导的铁死亡,敲低FPN加速铁死亡。

临床怎么用

  • Erastin可能作为子宫内膜异位症的潜在治疗药物,但需进一步体内验证FPN功能。

局限性

  • 研究主要在原代人子宫内膜间质细胞中进行,FPN的体内功能需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Could erastin activate ferroptosis to regress endometriotic lesions? SUMMARY ANSWER: Erastin could induce ferroptosis to regress endometriotic lesions in endometriosis. WHAT IS KNOWN ALREADY: Ectopic endometrial stromal cells (EESCs) are in an iron overloading microenvironment and tend to be more sensitive to oxidative damage. The feature of erastin-induced ferroptosis is iron-dependent accumulation of lethal lipid reactive oxygen species (ROS). STUDY DESIGN, SIZE, DURATION: Eleven patients without endometriosis and 21 patients with endometriosis were recruited in this study. Primary normal and ectopic endometrial stromal cells were isolated, cultured and subjected to various treatments. The in vivo study involved 10 C57BL/6 female mice to establish the model of endometriosis. PARTICIPANTS/MATERIALS, SETTING, METHODS: The markers of ferroptosis were assessed by cell viability, lipid peroxidation level and morphological changes. The cell viability was measured by colorimetric method, lipid peroxidation levels were measured by flow cytometry, and morphological changes were observed by transmission electron microscopy. Immunohistochemistry and western blot were used to detect ferroportin (FPN) expression. Prussian blue staining and immunofluorescent microscopy of catalytic ferrous iron were semi-quantified the levels of iron. Adenovirus-mediated overexpression and siRNA-mediated knockdown were used to investigate the role of FPN on erastin-induced ferroptosis in EESCs. MAIN RESULTS AND THE ROLE OF CHANCE: EESCs were more susceptible to erastin treatment, compared to normal endometrial stromal cells (NESCs) (P<0.05). Treatment of cultured EESCs with erastin dramatically increased the total ROS level (P<0.05, versus control), lipid ROS level (P<0.05, versus NESCs) and intracellular iron level (P<0.05, versus NESCs). The cytotoxicity of erastin could be attenuated by iron chelator, deferoxamine (DFO), and ferroptosis inhibitors, ferrostatin-1 and liproxstatin-1, (P<0.05, versus erastin) in EESCs. In EESCs with erastin treatment, shorter and condensed mitochondria were observed by electron microscopy. These findings together suggest that erastin is capable to induce EESC death by ferroptosis. However, the influence of erastin on NESCs was slight. The process of erastin-induced ferroptosis in EESCs accompanied iron accumulation and decreased FPN expression. The overexpression of FPN ablated erastin-induced ferroptosis in EESCs. In addition, knockdown of FPN accelerated erastin-induced ferroptosis in EESCs. In a mouse model of endometriosis, we found ectopic lesions were regressed after erastin administration. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: This study was mainly conducted in primary human endometrial stromal cells. Therefore, the function of FPN in vivo need to be further investigated. WIDER IMPLICATIONS OF THE FINDINGS: Our findings reveal that erastin may serve as a potential therapeutic treatment for endometriosis. STUDY FUNDING/COMPETING INTEREST(S): This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. The authors declare no conflict of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Li Y, Zeng X, Lu D, et al. Erastin induces ferroptosis via ferroportin-mediated iron accumulation in endometriosis. Hum Reprod. 2021. PMID: 33378529. doi:10.1093/humrep/deaa363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。